Valbiotis Accelerates Its Marketing Strategy
Retrieved on:
Friday, October 7, 2022
Biotechnology, Pharmaceutical, Health, Cardiology, Union, AMF, Risk, Development, AEC, ERDF, Growth, European Regional Development Fund, Pharmacy, NAFL, Lists of diseases, Research and development, Patient, Investor, LDL, Cropping system, Research, TOTUM, Blood pressure, PEA, Partnership, NASH, IFREMER, Company, Marketing, Pathology, TOP, IFOP, Prediabetes, BPI, Medicine, Pharmacist, Degenerative disease, DNA, Heart, Practitioner, Solution, Pharmaceutical industry, Dietary supplement, Aquaculture
Valbiotis (FR0013254851 ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.
Key Points:
- Valbiotis (FR0013254851 ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.
- At the same time, consumers/patients will be targeted directly through an adapted digital marketing strategy.
- For more information about Valbiotis, please visit: www.valbiotis.com
This press release contains forward-looking statements about Valbiotis objectives. - Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.